title: Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.
abstract: Cancer is a complex disease resulting from the uncontrolled proliferation of cell signaling events. Protein kinases have been identified as central molecules that participate overwhelmingly in oncogenic events, thus becoming key targets for anticancer drugs. A majority of studies converged on the idea that ligand-binding pockets of kinases retain clues to the inhibiting abilities and cross-reacting tendencies of inhibitor drugs. Even though these ideas are critical for drug discovery, validating them using experiments is not only difficult, but also in some cases infeasible. To overcome these limitations and to test these ideas at the molecular level, we present here the results of receptor-focused in-silico docking of nine marketed drugs to 19 different wild-type and mutated kinases chosen from a wide range of families. This investigation highlights the need for using relevant models to explain the correct inhibition trends and the results are used to make predictions that might be able to influence future experiments. Our simulation studies are able to correctly predict the primary targets for each drug studied in majority of cases and our results agree with the existing findings. Our study shows that the conformations a given receptor acquires during kinase activation, and their micro-environment, defines the ligand partners. Type II drugs display high compatibility and selectivity for DFG-out kinase conformations. On the other hand Type I drugs are less selective and show binding preferences for both the open and closed forms of selected kinases. Using this receptor-focused approach, it is possible to capture the observed fold change in binding affinities between the wild-type and disease-centric mutations in ABL kinase for Imatinib and the second-generation ABL drugs. The effects of mutation are also investigated for two other systems, EGFR and B-Raf. Finally, by including pathway information in the design it is possible to model kinase inhibitors with potentially fewer side-effects.
authors: Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research (FNLCR), P.O. Box B, Frederick, MD 21702, USA. Electronic address: ravichandrans@mail.nih.gov.
authors: Sarangan
authors: S
authors: Ravichandran
authors: Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research (FNLCR), P.O. Box B, Frederick, MD 21702, USA.
authors: Brian T
authors: BT
authors: Luke
authors: Advanced Biomedical Computing Center, Frederick National Laboratory for Cancer Research (FNLCR), P.O. Box B, Frederick, MD 21702, USA.
authors: Jack R
authors: JR
authors: Collins
mesh_terms: D000595:Amino Acid Sequence; D045744:Cell Line, Tumor; D018360:Crystallography, X-Ray; D030562:Databases, Protein; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000737:chemistry; D006801:Humans; D000068877:Imatinib Mesylate / Q000737:chemistry / Q000494:pharmacology; D007700:Kinetics; D008024:Ligands; D008958:Models, Molecular; D062105:Molecular Docking Simulation; D008969:Molecular Sequence Data; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000737:chemistry; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D016415:Sequence Alignment; D013816:Thermodynamics
chemical_list: D008024:Ligands; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; D048493:Proto-Oncogene Proteins B-raf
keywords: Activity; Biological Pathways; Cross-reactivity; Docking; Kinase drugs; Mutation
references: Clin Cancer Res. 2006 Nov 1;12(21):6494-501
references: 17085664
references: Cell. 2003 Mar 21;112(6):859-71
references: 12654251
references: J Biol Chem. 1992 May 25;267(15):10588-95
references: 1375224
references: Nat Rev Cancer. 2010 Feb;10(2):130-7
references: 20094047
references: J Med Chem. 2009 Jul 9;52(13):3915-26
references: 19462975
references: J Biol Chem. 2004 Dec 31;279(53):55827-32
references: 15507431
references: Anticancer Res. 2011 Mar;31(3):789-95
references: 21498698
references: Cancer Cell. 2005 Feb;7(2):129-41
references: 15710326
references: PLoS One. 2011;6(7):e22644
references: 21818358
references: J Comput Chem. 2009 Dec;30(16):2785-91
references: 19399780
references: Annu Rev Biophys Biomol Struct. 2007;36:21-42
references: 17201676
references: J Comput Aided Mol Des. 2002 Jan;16(1):11-26
references: 12197663
references: Science. 2002 Dec 6;298(5600):1912-34
references: 12471243
references: Proteins. 2008 Mar;70(4):1451-60
references: 17910071
references: Cancer Cell. 2011 Apr 12;19(4):556-68
references: 21481795
references: J Med Chem. 2005 Jun 16;48(12):4111-9
references: 15943484
references: J Med Chem. 2004 Jun 3;47(12):2977-80
references: 15163179
references: Cancer Cell. 2007 Mar;11(3):217-27
references: 17349580
references: J Med Chem. 2008 Dec 25;51(24):7921-32
references: 19053777
references: Nat Chem Biol. 2011 Apr;7(4):200-2
references: 21336281
references: Clin Cancer Res. 2006 Oct 1;12(19):5764-9
references: 17020982
references: J Mol Recognit. 1996 Jan-Feb;9(1):1-5
references: 8723313
references: Q Rev Biophys. 2009 Feb;42(1):1-40
references: 19296866
references: J Biol Chem. 2006 Oct 27;281(43):32714-23
references: 16943190
references: Clin Cancer Res. 2010 Apr 1;16(7):1973-8
references: 20215532
references: Nat Biotechnol. 2008 Jan;26(1):127-32
references: 18183025
references: J Biol Chem. 2002 Nov 29;277(48):46265-72
references: 12196540
references: N Engl J Med. 2001 Apr 5;344(14):1031-7
references: 11287972
references: Cancer Res. 2004 Sep 15;64(18):6652-9
references: 15374980
references: J Biol Chem. 2004 Jul 23;279(30):31655-63
references: 15123710
references: J Am Chem Soc. 2011 Jun 22;133(24):9181-3
references: 21545110
references: Nat Chem Biol. 2008 Nov;4(11):691-9
references: 18849971
references: Chem Biol Drug Des. 2010 Aug;76(2):154-63
references: 20545945
references: J Med Chem. 2008 Sep 11;51(17):5149-71
references: 18710211
references: Nat Rev Drug Discov. 2004 Dec;3(12):1001-10
references: 15573099
references: FEBS Lett. 2006 Feb 20;580(5):1447-50
references: 16460734
references: WormBook. 2005;:1-19
references: 18050405
references: Structure. 2008 Mar;16(3):460-7
references: 18334220
references: Cell. 2004 Mar 19;116(6):855-67
references: 15035987
references: Nat Rev Drug Discov. 2004 Nov;3(11):935-49
references: 15520816
references: Nat Genet. 2006 Mar;38(3):294-6
references: 16474404
references: J Clin Oncol. 2009 Jan 20;27(3):469-71
references: 19075254
references: PLoS Med. 2005 Mar;2(3):e73
references: 15737014
references: J Comput Chem. 2010 Jan 30;31(2):455-61
references: 19499576
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: PLoS One. 2013;8(12):e83922
references: 24391846
references: Science. 2007 Oct 12;318(5848):287-90
references: 17872411
references: Drug Discov Today. 2012 Apr;17(7-8):388-95
references: 22326379
references: Nat Chem Biol. 2006 Jul;2(7):358-64
references: 16783341
references: Chem Rev. 2001 Aug;101(8):2209-42
references: 11749371
references: Nat Biotechnol. 2011 Nov;29(11):1039-45
references: 22037377
references: Neoplasia. 2010 Mar;12(3):214-23
references: 20234815
references: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references: 24399786
references: Protein Sci. 2010 Mar;19(3):429-39
references: 20052711
references: Chem Biol. 2010 Nov 24;17(11):1241-9
references: 21095574
references: J Comput Aided Mol Des. 1996 Aug;10(4):293-304
references: 8877701
references: J Med Chem. 2010 Apr 8;53(7):2681-94
references: 20000735
references: PLoS One. 2012;7(4):e29828
references: 22493660
references: Nat Biotechnol. 2011 Nov;29(11):1046-51
references: 22037378
references: Nat Struct Biol. 1994 Jan;1(1):65-9
references: 7656010
references: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2070-5
references: 18227510
references: J Biol Chem. 2009 Jan 2;284(1):284-91
references: 18984583
references: BMC Biol. 2011;9:71
references: 22035460
references: J Chem Theory Comput. 2010 Nov 9;6(11):3540-3557
references: 22639555
references: Protein Sci. 2002 Jul;11(7):1729-37
references: 12070326
references: Gastroenterology. 2004 Jul;127(1):294-9
references: 15236194
references: Structure. 2007 Mar;15(3):299-311
references: 17355866